PRECLINICAL AND CLINICAL EFFICACY OF ENTRECTINIB IN PRIMARY AND METASTATIC BRAIN TUMORS HARBORING NTRK, ROS1, OR ALK GENE FUSIONS

Rangaraju S.; Farago A.; Heym K. M.; Ahn M.; Drilon A.; Potts S.; Hornby Z.; Multani P.; Li G.

首页> 外文期刊>Neuro-Oncology >PRECLINICAL AND CLINICAL EFFICACY OF ENTRECTINIB IN PRIMARY AND METASTATIC BRAIN TUMORS HARBORING NTRK, ROS1, OR ALK GENE FUSIONS

【24h】

PRECLINICAL AND CLINICAL EFFICACY OF ENTRECTINIB IN PRIMARY AND METASTATIC BRAIN TUMORS HARBORING NTRK, ROS1, OR ALK GENE FUSIONS

机译：Entrettinib在携带NTRK，ROS1或ALK基因融合蛋白的原发和转移性脑肿瘤中的临床和临床疗效

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Neuro-Oncology》 |2017年第3期|106-106|共1页
作者
Rangaraju S.; Farago A.; Heym K. M.; Ahn M.; Drilon A.; Potts S.; Hornby Z.; Multani P.; Li G.;
展开▼
作者单位

Ignyta Inc, San Diego, CA USA;

Massachusetts Gen Hosp, Boston, MA 02114 USA;

Cook Childrens Med Ctr, Ft Worth, TX USA;

Samsung Med Ctr, Seoul, South Korea;

Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA;

Ignyta Inc, San Diego, CA USA;

Ignyta Inc, San Diego, CA USA;

Ignyta Inc, San Diego, CA USA;

Ignyta Inc, San Diego, CA USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of NTRK, ROS1, and ALK fusion-positive solid tumors [J] . Dazhi Liu, Michael Offin, Stephen Harnicar, Therapeutics and Clinical Risk Management . 2018,第2期

机译：Entrectinib：口服可用的选择性酪氨酸激酶抑制剂，用于治疗NTRK，ROS1和ALK融合阳性实体瘤
2. P2.06-002 Phase I Study of DS-6051b, a ROS1/NTRK Inhibitor, in Japanese Subjects with Advanced Solid Tumors Harboring Either a ROS1 or NTRK Fusion Gene [J] . Kaname Nosaki, Yutaka Fujiwara, Masayuki Takeda, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2017,第1期

机译：P2.06-002阶段I研究DS-6051B，一种ROS1 / NTRK抑制剂，日本受试者，具有晚期实体肿瘤，含有ROS1或NTRK融合基因
3. P2.06-002 Phase I Study of DS-6051b, a ROS1/NTRK Inhibitor, in Japanese Subjects with Advanced Solid Tumors Harboring Either a ROS1 or NTRK Fusion Gene [J] . Kaname Nosaki, Yutaka Fujiwara, Masayuki Takeda, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2017,第1期

机译：P2.06-002阶段I研究DS-6051B，一种ROS1 / NTRK抑制剂，日本受试者，具有晚期实体肿瘤，含有ROS1或NTRK融合基因
4. High-Depth Sequencing of Over 750 Genes Supports Linear Progression of Primary Tumors and Metastases in the Majority of Patients with Liver-Limited Metastatic Colorectal Cancer [C] . Simeen Malik, Iain Beehuat Tan, Kalpana Ramnarayanan, International Molecular Medicine Tri-Conference. . 2015

机译：超过750个基因的高深度测序支持肝脏有限转移性结直肠癌大多数患者的原发性肿瘤和转移的线性进展
5. Improving the Delivery of Novel Molecularly-targeted Therapies for the Treatment of Primary and Metastatic Brain Tumors [D] . Gampa, Gautham 2019

机译：改善新型分子靶向疗法在治疗原发性和转移性脑肿瘤中的作用
6. P14.19 Preclinical and clinical efficacy of entrectinib in primary and metastatic brain tumors harboring NTRK ROS1 or ALK gene fusions [O] . S. Rangaraju, A. Farago, K. M. Heym, 2017

机译：P14.19恩替替尼在具有NTRKROS1或ALK基因融合的原发性和转移性脑肿瘤中的临床前和临床疗效
7. TRTH-10. PEDIATRIC PHASE 1/1B STUDY OF ENTRECTINIB IN PATIENTS WITH PRIMARY BRAIN TUMORS, NEUROBLASTOMA, AND NTRK, ROS1, OR ALK FUSIONS [O] . Sunitha Rangaraju, Gang Li, Jason Christiansen, 2017

机译：Trth-10。小儿阶段1 / 1B对初级脑肿瘤，神经母细胞瘤和NTRK，ROS1或ALK融合患者entectinib的研究

PRECLINICAL AND CLINICAL EFFICACY OF ENTRECTINIB IN PRIMARY AND METASTATIC BRAIN TUMORS HARBORING NTRK, ROS1, OR ALK GENE FUSIONS

著录项

相似文献

相关主题

期刊订阅